Cancer of the uterine cervix: Dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment

Pourquier, H; Dubois, J.B.; Delard, R.

doi:10.1016/0360-3016(82)90446-1

Cited by 113 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their LDR series, Perez et al 30 and Pourquier et al 31 demonstrated a positive correlation between a dose to the rectum and bladder of Ͼ 80 Gy and severe complications. They reported that the rates of Grade 2 and 3 complications in the urinary tract and rectosigmoid colon were approximately 5% with doses Ͻ 75-80 Gy.…”

Section: Discussionmentioning

confidence: 96%

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Nakano

Kato

Ohno³

et al. 2004

Cancer

146

100

View full text Add to dashboard Cite

BACKGROUNDThe authors performed a long‐term follow‐up study to evaluate the efficacy and late toxicity of high‐dose rate intracavitary brachytherapy (HDR‐ICBT) for cervical carcinoma.METHODSFrom 1968 to 1986, 1148 patients with Stage IB to IVB squamous cell carcinoma of the cervix (staging was performed according to the International Federation of Gynecology and Obstetrics) were treated with a combination of external beam radiotherapy (EBRT) and HDR‐ICBT. For patients with early‐stage disease, 20 gray (Gy) of EBRT was delivered to the whole pelvis, followed by 24 Gy/4 fractions of HDR‐ICBT and 30 Gy of central‐shielding EBRT. For patients with advanced‐stage disease, 20–40 Gy of whole pelvic EBRT was administered, followed by 24 Gy/4 fractions of ICBT and 30–10 Gy of central‐shielding EBRT. The overall treatment time was approximately 6 weeks. Among survivors, the follow‐up rate was 98% and the median follow‐up duration was 22 years.RESULTSThe 10‐year pelvic tumor control rates were 93% for patients with Stage IB disease, 82% for patients with Stage II disease, and 75% for patients with Stage III disease. The 10‐year overall and cause‐specific survival rates were 74% and 89% for patients with Stage IB disease, 52% and 74% for patients with Stage II disease, and 42% and 59% for patients with Stage III disease, respectively. The 10‐year actuarial rates of major complications were 4.4% in the rectosigmoid colon, 0.9% in the bladder, and 3.3% in the small intestines.CONCLUSIONSThe results of the current study suggest that the combination of EBRT and HDR‐ICBT according to the authors' protocol provided outcomes that were comparable to those of the conventional low‐dose rate brachytherapy with acceptable rates of late complications in the treatment of cervical carcinoma. Cancer 2005. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 96%

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Nakano

Kato

Ohno³

et al. 2004

Cancer

146

100

View full text Add to dashboard Cite

show abstract

“…Pourquier et al (27), Stryker et al (28), and Montana and Fowler (29) showed that the incidence of complications increased sharply with the mean dose calculated from lateral radiographs at several points on the anterior surface of the rectum. Perez et al (30) found that doses calculated at specific points defined only with reference to the applicators also showed a strong correlation with complications.…”

Section: Incidence and Risk Factorsmentioning

confidence: 97%

Rectal bleeding and its management after irradiation for uterine cervical cancer

Chun

Kang

Kil

et al. 2004

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Since a good correlation between the dose to critical organs and complication rate and severity was found [4,6,16,17,24], with particular influence of the dose from brachytherapy [21,22], these modifications may be a way to improve therapeutic ratio of cervical cancer radiotherapy. However, all these improvements are secondary to restrictions put by applicator geometry extorted by patients' anatomical conditions.…”

mentioning

confidence: 97%

Einfluß der Geometrie von Brachytherapieapplikatoren auf die Dosisverteilung im Becken bei Patientinnen mit Zervixkarzinom

Senkus-Konefka

Kobierska

Jassem

et al. 1997

Strahlenther. Onkol.

View full text Add to dashboard Cite

show abstract

Cancer of the uterine cervix: Dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment

Cited by 113 publications

References 11 publications

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix

Rectal bleeding and its management after irradiation for uterine cervical cancer

Einfluß der Geometrie von Brachytherapieapplikatoren auf die Dosisverteilung im Becken bei Patientinnen mit Zervixkarzinom

Contact Info

Product

Resources

About